D2 partial agonists for relapse prevention in schizophrenia - the long-term view

被引：0
|
作者：
Correll, C. U. [1 ,2 ]
机构：
[1] Zucker Hillside Hosp, Hofstra North Shore LIJ Sch Med, Psychiat, Glen Oaks, NY USA
[2] Zucker Hillside Hosp, Recognit & Prevent Program, Glen Oaks, NY USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2019年 / 29卷
关键词：
ARIPIPRAZOLE;
D O I：
10.1016/j.euroneuro.2018.11.998
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
C.13.05
引用
收藏
页码：S630 / S630
页数：1
相关论文
共 50 条
  • [21] Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
    Rotella, David P.
    McFarlane, Geraldine R.
    Greenfield, Alexander
    Grosanu, Cristina
    Robichaud, Albert J.
    Denny, Rajiah Aldrin
    Feenstra, Rolf W.
    Nunez-Garcia, Sara
    Reinders, Jan-Hendrik
    van der Neut, Martina
    McCreary, Andrew
    Kruse, Chris G.
    Sullivan, Kelly
    Pruthi, Farhana
    Lai, Margaret
    Zhang, Jean
    Kowal, Dianne M.
    Carrick, Tikva
    Grauer, Steven M.
    Navarra, Rachel L.
    Graf, Radka
    Brennan, Julie
    Marquis, Karen L.
    Pausch, Mark H.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (19) : 5552 - 5555
  • [22] A new pharmacological strategy for schizophrenia: The partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole
    Costentin, J.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2009, 35 (01): : 66 - 72
  • [23] Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder
    Johnson, Douglas S.
    Choi, Chung
    Fay, Lorraine K.
    Favor, David A.
    Repine, Joseph T.
    White, Andrew D.
    Akunne, Hyacinth C.
    Fitzgerald, Lawrence
    Nicholls, Kim
    Snyder, Bradley J.
    Whetzel, Steven Z.
    Zhang, Liming
    Serpa, Kevin A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (09) : 2621 - 2625
  • [24] Long-term course and relapse prevention in the treatment of anorexia nervosa
    Pike, KM
    CONTEMPORARY NEUROPSYCHIATRY, 2001, : 443 - 448
  • [25] Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence
    Kiefer, F
    Andersohn, F
    Otte, C
    Wolf, K
    Jahn, H
    Wiedemann, K
    ACTA NEUROPSYCHIATRICA, 2004, 16 (05): : 233 - 238
  • [26] Long-term relapse prevention with risperidone in 215 schizophrenic patients
    Abelló, CU
    Bennasar, MR
    Del Valle, IO
    ACTAS ESPANOLAS DE PSIQUIATRIA, 2001, 29 (04): : 243 - 249
  • [27] Long-term efficacy of rabeprazole in the prevention of relapse in erosive GERD
    Breiter, J
    Lanza, F
    Caos, A
    Perdomo, C
    Barth, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (09): : S37 - S37
  • [28] LONG-TERM BIOAVAILABILITY OF SINGLE DOSES OF INTRAMUSCULAR VITAMIN D2
    Xu, Feng
    Dai, Dexing
    Sun, Ruoman
    Liu, Zhenming
    Lin, Xiaolin
    Li, Lusha
    Xing, Xiaoping
    Wang, Xiangbing
    Li, Chunlin
    Xie, Zhongjian
    ENDOCRINE PRACTICE, 2020, 26 (11) : 1244 - 1254
  • [29] LONG-TERM BIOAVAILABILITY OF THREE DOSES OF INTRAMUSCULAR VITAMIN D2
    Xu, F.
    Dai, D.
    Sun, R.
    Xie, Z.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S415 - S415
  • [30] Risperidone vs haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: A long-term double-blind comparison
    Csernansky, JG
    Okamoto, A
    BIOLOGICAL PSYCHIATRY, 2000, 47 (08) : 31S - 32S
12345